Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 19789305)

1.

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

Schubert I, Saul D, Nowecki S, Mackensen A, Fey GH, Oduncu FS.

MAbs. 2014 Jan-Feb;6(1):286-96.

2.

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.

Schappa JT, Frantz AM, Gorden BH, Dickerson EB, Vallera DA, Modiano JF.

Int J Cancer. 2013 Oct 15;133(8):1936-44. doi: 10.1002/ijc.28187. Epub 2013 Apr 25.

3.

Dual targeting strategies with bispecific antibodies.

Kontermann RE.

MAbs. 2012 Mar-Apr;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub 2012 Mar 1. Review.

4.

Programmable self-assembly of antibody-oligonucleotide conjugates as small molecule and protein carriers.

Gangar A, Fegan A, Kumarapperuma SC, Wagner CR.

J Am Chem Soc. 2012 Feb 15;134(6):2895-7. doi: 10.1021/ja210894g. Epub 2012 Feb 1.

5.

A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA.

Pancreas. 2012 Jul;41(5):789-96. doi: 10.1097/MPA.0b013e31823b5f2e.

6.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.

Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA.

J Neurooncol. 2011 Jun;103(2):255-66. doi: 10.1007/s11060-010-0392-5. Epub 2010 Sep 10.

7.

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE.

Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8.

8.

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA.

Pancreas. 2010 Aug;39(6):913-22. doi: 10.1097/MPA.0b013e3181cbd908.

9.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA.

Br J Cancer. 2009 Oct 6;101(7):1114-23. doi: 10.1038/sj.bjc.6605297.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk